Dolutegravir, a more recently approved antiretroviral drug, is taken once-a-day, is more tolerable, and is less likely to result in resistance mutations compared with...
When expensive medicines that are proven to prevent HIV acquisition are available through employer-sponsored health insurance (ESI), annual earnings for men in same-sex couples...
The global HIV response is in danger. Progress in prevention is faltering around the world. Action to tackle the inequalities driving AIDS is urgently...
UNAIDS welcomed the agreement between ViiV and the Medicines Patent Pool to enable access to generic formulation of long acting Cabotegravir for PrEP to...
A clinical trial of people living with HIV has found that treating anal precancerous growths known as high-grade squamous intraepithelial lesions (or HSIL) reduces...
Large-scale HIV screening and peer support to connect people who inject drugs to HIV care successfully reduced uncontrolled HIV in this population by more...